Marie Lund
Statens Serum Institut
32 Papers
46 Citations
Marie Lund is an academic researcher from Statens Serum Institut. The author has contributed to research in topics: Medicine & Cohort study. The author has an hindex of 12, co-authored 25 publications. Previous affiliations of Marie Lund include Frederiksberg Hospital & Aarhus University Hospital.
Chat about Author
Papers
Cancer Risk Among Patients With Myotonic Muscular Dystrophy
Shahinaz M. Gadalla,Marie Lund,Ruth M. Pfeiffer,Sanne Gørtz,Christine M. Mueller,Richard T. Moxley,Sigurdur Y. Kristinsson,Magnus Björkholm,Fatma M. Shebl,James E. Hilbert,Ola Landgren,Jan Wohlfahrt,Mads Melbye,Mark H. Greene +13 more
TL;DR: Patients with MMD identified from the Swedish and Danish patient registries were at increased risk of cancer both overall and for selected anatomic sites.
120
Clinical Implications of P-Glycoprotein Modulation in Drug–Drug Interactions
TL;DR: A comprehensive review of P-glycoprotein-mediated DDIs is conducted and a classification for individual drugs based on both in vitro and in vivo evidence (substrates, inhibitors and inducers) is suggested.
102
Concomitant use of low‐dose methotrexate and NSAIDs and the risk of serious adverse events among patients with rheumatoid arthritis
Henrik Svanström,Marie Lund,Mads Melbye,Mads Melbye,Mads Melbye,Björn Pasternak,Björn Pasternak +6 more
TL;DR: This study aimed to investigate the risk of serious adverse events associated with concomitant use of low‐dose methotrexate and NSAIDs, compared with use of metotrexate alone, among patients with rheumatoid arthritis.
59
Hereditary thrombophilia and recurrent pregnancy loss: a retrospective cohort study of pregnancy outcome and obstetric complications
Marie Lund,Henriette Svarre Nielsen,Thomas Vauvert F. Hviid,Rudi Steffensen,A. Nyboe Andersen,Ole Bjarne Christiansen,Ole Bjarne Christiansen +6 more
TL;DR: In the unadjusted analysis, FVL and PT mutations have a negative prognostic impact on the live birth rate in women with RPL; however, when adjusting for significant covariates, the results no longer reach statistical significance.
42
Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation
TL;DR: Among patients with NVAF in routine clinical practice, there were no statistically significant differences in risk of stroke or systemic embolism or major bleeding in propensity-matched comparisons between apixaban, dabigatran, and rivaroxaban used in standard doses.
30